Study of Ambrisentan in Subjects With Pulmonary Hypertension

This Phase 3, international, multicenter, open-label study will monitor the long-term safety
of ambrisentan in adults with pulmonary hypertension. The available ambrisentan doses for
this study are 5 or 10 mg administered orally once daily; the approved doses of ambrisentan
in the United States, Canada, and the European Union are 5 and 10 mg. Investigators will be
able to adjust ambrisentan dose as clinically indicated. A minimum of 4 weeks between dose
adjustments is required. Participants receiving other therapies for pulmonary hypertension
that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in
this study and continue to receive such therapies. Participants enrolled in this study will
receive treatment with ambrisentan until such time as the investigator or participant chooses
to stop ambrisentan treatment, ambrisentan becomes commercially available, or the Sponsor
stops the study.